Faslodex (fulvestrant): Reviews and patient testimonials
Back to the list of medications
Medication indications
Faslodex 250 mg solution for injection
Faslodex is indicated:
• as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- not previously treated with endocrine therapy, or
- with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.
• in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
Route of administration: Injectable
Molecule: fulvestrant
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.